论文部分内容阅读
目的研究沐舒坦在治疗重症新生儿肺炎中的临床疗效和安全性。方法 50例重症新生儿肺炎患儿,随机分为实验组和对照组,各25例。实验组使用沐舒坦进行治疗,对照组则使用常规治疗方式进行治疗,观察两组新生儿临床疗效和安全性。结果实验组经治疗后总有效率为96.0%高于对照组的76.0%,差异具有统计学意义(P<0.05)。两组新生儿的呼吸困难好转时间、发绀好转时间、住院时间以及肺部杂音好转时间比较,差异有统计学意义(P<0.05)。结论使用沐舒坦治疗重症新生儿肺炎能够明显改善患儿的病情,且安全可靠,值得在临床推广使用。
Objective To study the clinical efficacy and safety of mucosolvan in the treatment of severe neonatal pneumonia. Methods Fifty cases of severe neonatal pneumonia were randomly divided into experimental group and control group, with 25 cases in each. The experimental group was treated with mucosolvan, while the control group received conventional treatment, and the clinical efficacy and safety of the two groups were observed. Results The total effective rate of the experimental group after treatment was 96.0% higher than 76.0% of the control group, the difference was statistically significant (P <0.05). Two groups of newborns with dyspnea improved time, cyanotic improved time, hospital stay and pulmonary murmur improved time, the difference was statistically significant (P <0.05). Conclusion Mucosolvan in the treatment of severe neonatal pneumonia can significantly improve the condition of children and is safe and reliable, so it is worth to be used clinically.